바이오리더스
ABOUT
Management
Philosophy
History
CEO Greetings
Executives
Affiliates
Partner Companies
Contact us
BUSINESS
Medicine Business
Consumer Business
R&D
P53 Target Anti-Cancer
Platform Technology
Pipeline
Papers and Patents
IR
Notices
Stock Information
PR Center
mall
GPGAmall
KR
EN
Pipeline
이전 버튼
다음버튼
P53 Target Anti-Cancer
Platform Technology
Pipeline
Papers and Patents
Pipeline
BLS-H01
BLS-H03
BLS-M07
BLS-M22
Clinical Development
Clinical Development
Notice
*CIN: Cervical Intraepithelial Neoplasia
**DMD: Duchenne Muscular Dystrophy
+BLS-M22: Orphan Drug Designation in FDA & MFDS
z
